The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Moving up where? we won't go anywhere until we get some new on approvals and sales. We weren't give any time line. Just have to hope. Pretty ridiculous stuff, but that's why were are all losing at the moment.
I hold quite a few ‘covid plays’. I have just reread the trading update RNS and looked around the web page. I must say i’m pretty envious of those buying now. For me to average down here i’d have to sell elsewhere or sell here hoping to buy back lower. Neither of which I am prepared to do.
Imo the approvals will come and it will lift. The rapid test poc is the buggy, end of year.
Trek
yes AVCT will drift lower too
Jh
And you'll have to wait patiently even longer for approvals at AVCT.
AVCT have the same partner, Cytiva, as GDR, and there's not even a test available yet at AVCT to be approved.
Expecting AVCT to drift down further too ?
Apples and Oranges
#AVCT could be monumentally overvalued, but the Ruane/Cuniff fund seem to think £10m at £1.20 is a good price so what can you do
I like #GDR and the current market cap is attractive if you believe the antigen market has a lot more to give over the next 12 months
I am a holder in both AVCT and GDR. To date the CEO of Avct hasnt put a foot wrong regarding marketing. Our GDR CEO unfortunately has done nothing right recently.
We must now wait patiently here for approvals. Until then it drifts lower every day is my reading
GLR
Given that AVCT are valued 7.5 times higher than GDR, at around £300 Million, without a test available yet and by default, equally, zero sales, AVCT are far higher risk than GDR at present.
At this point in time I wish I picked Avct ovet GDR.
They partnered with modern water this morning g and certainly know how to sell to investors.
GDR, great tech and product. To date, a lack of urgency and competence in getting it to market.
No excuses for delays on approvals. They should of applied immidiately considering it is our 'key' market.
LB28 are you on about these two?
- PCR swab based - not portable so cannot be used in a airport setting / care home
- Rapid antigen testing on the way through SONA and AVCT could displace the market
The GDR 96 SARS-CoV-2 Assay is a Swab Based Antigen Test isn't it? Or am I wrong, apologies if so
I know they are 'developing' a rapid point of care test which uses Saliva and can generate results in 30 minutes, so that can be used in a care home / airport but they are not looking to have that developed until the end of the year, so IMO that is a con at the moment because there are other companies which can take a huge slice of that market, any idea why they are not rushing this to market, maybe they are hugely confident in the PCR test (which is better than any current product out there)
As I said there are pros and cons, I put the portable test as a con for now because there will be other portable tests on the market way before GDR release theirs, but as mentioned if their PCR test is the best in class (which it looks like it is) then large sales should not be far away!
LB
Given that he states it will be value for money if sales of the test increase and the market cap reduces, his third 'con' needs more research too.
He's invested in AVCT, so sees that as 'good value', whose market cap is 7.5 times higher than GDR with zero sales of their test because it isn't even available yet.
Forked tongue.
Really tanking here but IF they can bring in any sort of decent revenue in August (£5-10m) then it will look very cheap again
CE mark 22nd May is what has dissapointed me, they have had nearly 2 months and only booked £1m of INDICATED orders, pending approvals
Why are they struggling so much to book orders when it has been CE marked? For comparison NCYT 2 months after CE marking their product, booked £17.8m - yes of course they was first to market
Hopefully Cytiva have a trick up their sleeve otherwise it seems like a pointless collaboration, they have already done well with $SONA (Sona Nanotech) yet to see how the #AVCT partnership will turn out
Pros
MCAP compared to everyone else
PCR test with fewer steps than competitors/easier to use
High Spec Sens
Urgent unmet need for increasing testing capacity
Cons
PCR swab based - not portable so cannot be used in a airport setting / care home
Rapid antigen testing on the way through SONA and AVCT could displace the market
£1m indicated sales only after nearly 2 months of CE marking
Tough one to call as the upside could be significant on approvals, I may re-take a position if it drops to 60-70 as a high risk high reward play